Hier, habe ich vom ragingbull message board:
CYPT NEWS - CapStone Investments Announces Investment Opinion on Calypte Biomedical
Business Wire - January 30, 2004 12:10
SAN DIEGO, Jan 30, 2004 (BUSINESS WIRE) -- CapStone Investments Initiates Coverage of Calypte Biomedical with a "Long-Term Buy" Recommendation and $2 Price Target
CapStone Investments, a full-service investment firm, announced today that it has initiated coverage of Calypte Biomedical with a "Long-Term Buy" and a price target of $2. The report was written by Jason Diamond, the Director of Research.
CapStone Investments makes its research reports available in real-time to institutional investors through Multex at www.multex.com, Thomson Financial-First Call at www.firstcall.com and Research Edge at www.zackspro.com/edge, a product of Zack's Investment Research Inc.
About CapStone Investments
CapStone Investments (www.capstoneinvestments.com), based in San Diego, Calif., with its Research Division in Milwaukee, Wis., is a full-service investment firm, servicing a multi-billion dollar institutional account base. CapStone Investments is a member of the National Association of Securities Dealers (NASD), the Securities Investment Protection Corporation (SIPC) and the Municipal Securities Rulemaking Board (MSRB). CapStone Institutional Services (CapStone) is a division of CapStone Investments. CapStone is a dedicated alternative investment specialist focused on providing comprehensive service to the alternative investment manager.
SOURCE: CapStone Investments
For: CapStone Investments
Jason Diamond, 414-223-4401
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.